

PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	er the raperwork reduction rece		Application Number	10/630,590						
			Filing Date	July 29, 2003						
	TRANSMIT	TAL	First Named Inventor	LU, PETER S.						
	FORM		Group Art Unit							
	(to be used for all correspondent	e after initial filing)	Examiner Name							
		Submission 3 + refs.	Attorney Docket Number	VITA-008						
Total Number of Pages in This Submission   3 + refs.   Attorney Docker Number   VITA-000    ENCLOSURES (check all that apply)										
	Fee Transmittal Form  Fee Attached  Amendment / Reply  After Final  Affidavits/declaration( Extension of Time Request Express Abandonment Rec Information Disclosure Stat Certified Copy of Priority Documents  Response to Missing Parts. Incomplete Application  Response to Missing under 37 CFR 1.52 of	Assig (for a Drawing Licen)    Detition   Petition   Petition   Province   Power   Chan   Address   Term   Require   CD, No	nment Papers In Application) Ing(s) Ising-related Papers In to Convert to a Isional Application In of Attorney, Revocation Inge of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences  Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please identify below):  1. PTO/SB/08A 2. Copies of non-patent cited references 3. Postcard						
Signature OF APPLICANT, ATTORNEY, OR AGENT  Signing Attorney/Agent (Reg. No.)  Signature  Signature										
Date September 9, 2003  EXPRESS MAIL LABEL NO. EV333999061US										

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## Express Mail No. EV333999061US

INFORMATION	Attorney Docket	VITA-008		
DISCLOSURE STATEMENT	First Named Inventor	LU, PETER S.		
	Application Number	10/630,590		
	Confirmation No.			
	Filing Date	July 29, 2003		
Address to: Commissioner for Patents	Group Art Unit			
P.O. Box 1450	Examiner Name			
Alexandria, VA 22313-1450	Title: "METHODS OF DIAGNOSING CERVICAL			

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

CANCER"

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. VITA-008 may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: September 9, 2003

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

Dv.

James S. Keddie, Ph.D. Registration No. 48,920 SEP 0 9 2003

Examiner

Signature

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Appendicute for form 1449A/PTO				Complete if Known							
					Applicat	Application Number		10/630.590			
INFORMATION DISCLOSURE						Filing Date		July 29, 2003			
	STATEMENT BY APPLICANT					med Inventor	LU, PETER S.				
					Art Unit						
	(use as many sheets as necessary)				Examiner Name						
Sheet		1	of	1		Docket Number	VITA	\-008			
}				II S PA	<u></u>						
U.S. PATENT DOCUMENTS  Pages, Columns, Lines, W											
Examiner Cite Initials' No.1		Number-Kind Code <sup>2</sup> (if known)			tion Date D-YYYY	Name of Patentee Applicant of Cited Document	or Relevant Passages or Relevant				
		US- 4,777,239									
		US- 5,415,995									
		US- 5,648,459									
		US- 5,665,535									
		US- 5,753,233						100-100-100-100-100-100-100-100-100-100			
		US- 5,876,723					I				
		US-6,322,794					ĺ		***************************************		
		US- 6,344,314									
		US- 6,391,539									
		OTHER	PRIC	R ART—NO	N PATEN	T LITERATURE D	ocui	MENTS			
Examiner	Cite	Include n	ame of	the author (in CA	PITAL LETT	ERS), title of the article (	when a	poropriate), title of the			
Initials*	No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),									
		GARDIOL et al., ONCOGENIC HUMAN PAPILLOMAVIRUS E6 PROTEINS TARGET THE DISCS LARGE TUMOUR SUPPRESSOR FRO PROTEASOME-MEDIATED DEGRADATION, Oncogene, (1999), 18:5487-96									
		GLAUNSINGER et al., INTERACTIONS OF THE PDZ-PROTEIN MAGI-1 WITH ADENOVIRUS E4-ORF1 AND HIGH-RISK PAPILLOMAVIRUS E6 ONCOPROTEINS, Oncogene, (2000), 19:5270-80									
		KIYONO et al., BINDING OF HIGH-RISK HUMAN PAPILLOMAVIRUS E6 ONCOPROTEINS TO THE HUMAN HOMOLOGUE OF THE DROSOPHILA DISCS LARGE TUMOR SUPPRESSOR PROTEIN, Proc. Natl. Acad. Sci., (1997), 94:11612-6  LEE et al., BINDING OF HUMAN VIRUS ONCOPROTEINS TO HDLG/SAP97, A MAMMALIAN HOMOLOG OF THE DROSOPHILA DISCS LARGE TUMOR SUPPRESSOR PROTEIN, Proc. Natl. Acad. Sci., (1997), 94:6670-5									
		MESCHEDE et al., ANTIBODIES AGAINST EARLY PROTEINS OF HUMAN PAPILLOMAVIRUSES AS DIAGNOSTIC MARKERS FOR INVASIVE CERVICAL CANCER, J. Clin. Microbiol., (1998), 36:475-80									
		MUNGER et al., THE ROLE OF HUMAN PAPILLOMAVIRUSES IN HUMAN CANCERS, Front. Biosci., (2002), 7:d641-9									
		PIM et al., HPV-18 BINDING TO FULI	E6*I F	PROTEIN MOD GTH HPV-18 E	ULATES T 6, Oncoger	HE E6-DIRECTED Date, (1999), 18:7403-8	DEGRA	ADATION OF P53 BY			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Date

This collection of information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.